Sale!

Atazanavir Sulphate

150.00

Applications

Atazanavir (formerly known as BMS-232632) is an antiretroviral drug of the protease inhibitor (PI) class. Like other antiretrovirals, it is used to treat infection of human immunodeficiency virus (HIV).

Description

Atazanavir Sulfate is a sulfate salt form of atazanavir, an aza-dipeptide analogue with a bis-aryl substituent on the (hydroxethyl)hydrazine moiety with activity against both wild type and mutant forms of HIV protease. Atazanavir does not elevate serum lipids, a common problem with other protease inhibitors.

Preparation

According to an aspect of the present invention, there is provided a process for the preparation of Compound (A) that comprises preparing atazanavir sulphate by treating atazanavir base (Compound (II)) with sulphuric acid in a combination of solvents, and isolating Compound (A).

Chemical Properties

Atazanavir sulfate is a white to pale yellow crystalline powder with low solubility in water, known for its antiviral properties, and is a vital component in the treatment of HIV infection.

Definition

Atazanavir sulfate is a sulfated derivative of atazanavir, a protease inhibitor used in the treatment of HIV/AIDS by inhibiting the HIV protease enzyme.

Description

Product Name Atazanavir Sulphate
Brand indian
Country of Origin Made in India
Usage Pharma
Formula C38H54N6O11S
Molar Mass 704.856 g/mol
CAS ID 198904-31-3
Elimination half-life 6.5 hrs
Bioavailability 68%
Molecular Weight 802.94
Melting point 195.0°, or acetone; mp 198-199° (dec)
alpha D22 -46.1° (c = 1 in 1:1 CH3OH/H2O, pH = 2.6)
storage temp under inert gas (nitrogen or Argon) at 2-8°C
solubility ≥28.7 mg/mL in DMSO with gentle warming; insoluble in H2O; ≥4.05 mg/mL in EtOH with gentle warming and ultrasonic
form Powder
Packaging Size As Per Requirement

Our Export Location as a Atazanavir Sulphate Manufacturer, Supplier, Exporter, Stockist from India.

Afghanistan

Albania

Algeria

Andorra

Angola

Antigua and Barbuda

Argentina

Armenia

Australia

Austria

Austrian Empire

Azerbaijan

Baden

Bahamas

Bahrain

Bangladesh

Barbados

Bavaria

Belarus

Belgium

Belize

Benin (Dahomey)

Bolivia

Liberia

Libya

Liechtenstein

Lithuania

Luxembourg

Madagascar

Malawi

Malaysia

Maldives

Mali

Malta

Marshall Islands

Mauritania

Mauritius

Mecklenburg-Schwerin

Mecklenburg-Strelitz

Mexico

Micronesia

Moldova

Monaco

Mongolia

Montenegro

Bosnia and Herzegovina

Botswana

Brazil

Brunei

Brunswick and Lüneburg

Bulgaria

Burkina Faso

Burma

Burundi

Cabo Verde

Cambodia

Cameroon

Canada

Cayman Islands

Central African Republic

Central American Federation

Chad

Chile

China

Colombia

Comoros

Congo Free State

Costa Rica

Morocco

Mozambique

Namibia

Nassau

Nauru

Nepal

Netherlands

New Zealand

Nicaragua

Niger

Nigeria

North German Confederation

North German Union

North Macedonia

Norway

Oldenburg

Oman

Orange Free State

Pakistan

Palau

Panama

Papal States

Cote d’Ivoire

Croatia

Cuba

Cyprus

Czechia

Czechoslovakia

Democratic Republic of the Congo

Denmark

Djibouti

Dominica

Dominican Republic

Duchy of Parma

East Germany

Ecuador

Egypt

El Salvador

Equatorial Guinea

Eritrea

Estonia

Eswatini

Ethiopia

Federal Government of Germany

Fiji

Papua New Guinea

Paraguay

Peru

Philippines

Piedmont-Sardinia

Poland

Portugal

Qatar

Republic of Genoa*

Republic of Korea (South Korea)

Republic of the Congo

Romania

Russia

Rwanda

Saint Kitts and Nevis

Saint Lucia

Saint Vincent and the Grenadines

Samoa

San Marino

Sao Tome and Principe

Saudi Arabia

Schaumburg-Lippe*

Finland

France

Gabon

Gambia

Georgia

Germany

Ghana

Grand Duchy of Tuscany

Greece

Grenada

Guatemala

Guinea

Guinea-Bissau

Guyana

Haiti

Hanover

Hanseatic Republics

Hawaii

Hesse

Holy See

Honduras

Hungary

Iceland

Senegal

Serbia

Seychelles

Sierra Leone

Singapore

Slovakia

Slovenia

Solomon Islands

Somalia

South Africa

South Sudan

Spain

Sri Lanka

Sudan

Suriname

Sweden

Switzerland

Syria

Tajikistan

Tanzania

Texas

Thailand

India

Indonesia

Iran

Iraq

Ireland

Israel

Italy

Jamaica

Japan

Jordan

Kazakhstan

Kenya

Kingdom of Serbia/Yugoslavia

Kiribati

Korea

Kosovo

Kuwait

Kyrgyzstan

Laos

Latvia

Lebanon

Lesotho

Lew Chew (Loochoo)

Timor-Leste

Togo

Tonga

Trinidad and Tobago

Tunisia

Turkey

Turkmenistan

Tuvalu

Two Sicilies*

Uganda

Ukraine

Union of Soviet Socialist Republics*

United Arab Emirates

United Kingdom

Uruguay

Uzbekistan

Vanuatu

Venezuela

Vietnam

Württemberg*

Yemen

Zambia

Zimbabwe

Reviews

There are no reviews yet.

Be the first to review “Atazanavir Sulphate”

Your email address will not be published. Required fields are marked *